{
    "organizations": [],
    "uuid": "05957f283c7b2d997434f58c3f38682f8551e707",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biotime-further-expands-opregen-cl/brief-biotime-further-expands-opregen-clinical-trial-in-dry-amd-with-the-opening-of-two-additional-u-s-sites-idUSASC0A3IR",
    "ord_in_thread": 0,
    "title": "BRIEF-BioTime Further Expands Opregen Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 24 (Reuters) - BioTime Inc:\n* BIOTIME FURTHER EXPANDS OPREGENÂ® CLINICAL TRIAL IN DRY-AMD WITH THE OPENING OF TWO ADDITIONAL U.S. SITES\n* BIOTIME INC - EXPANSION OF ONGOING PHASE I/IIA CLINICAL TRIAL FOR OPREGEN, WITH ADDITION OF TWO NEW U.S. SITES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-24T19:24:00.000+03:00",
    "crawled": "2018-05-25T16:31:25.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "biotime",
        "inc",
        "biotime",
        "expands",
        "clinical",
        "trial",
        "opening",
        "two",
        "additional",
        "site",
        "biotime",
        "inc",
        "expansion",
        "ongoing",
        "phase",
        "clinical",
        "trial",
        "opregen",
        "addition",
        "two",
        "new",
        "site",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}